155 related articles for article (PubMed ID: 37562608)
1. PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
Vanderlinden E; Boonen A; Noppen S; Schoofs G; Imbrechts M; Geukens N; Snoeck R; Stevaert A; Naesens L; Andrei G; Schols D
Antiviral Res; 2023 Sep; 217():105700. PubMed ID: 37562608
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
4. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
[TBL] [Abstract][Full Text] [Related]
5. ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin.
Partridge LJ; Urwin L; Nicklin MJH; James DC; Green LR; Monk PN
Cells; 2021 Jun; 10(6):. PubMed ID: 34200372
[TBL] [Abstract][Full Text] [Related]
6. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.
Vanhulle E; D'huys T; Provinciael B; Stroobants J; Camps A; Noppen S; Schols D; Van Damme EJM; Maes P; Stevaert A; Vermeire K
Front Cell Infect Microbiol; 2022; 12():989534. PubMed ID: 36111239
[No Abstract] [Full Text] [Related]
8. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
9. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
Palla SR; Li CW; Chao TL; Lo HV; Liu JJ; Pan MY; Chiu YT; Lin WC; Hu CW; Yang CM; Chen YY; Fang JT; Lin SW; Lin YT; Lin HC; Kuo CJ; Wang LH; Chang SY; Liang PH
Antiviral Res; 2023 Nov; 219():105735. PubMed ID: 37858764
[TBL] [Abstract][Full Text] [Related]
11. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
[TBL] [Abstract][Full Text] [Related]
12. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
13. Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants.
Gelbach AL; Zhang F; Kwon SJ; Bates JT; Farmer AP; Dordick JS; Wang C; Linhardt RJ
Front Mol Biosci; 2022; 9():912887. PubMed ID: 36046608
[TBL] [Abstract][Full Text] [Related]
14. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
Gangadevi S; Badavath VN; Thakur A; Yin N; De Jonghe S; Acevedo O; Jochmans D; Leyssen P; Wang K; Neyts J; Yujie T; Blum G
J Phys Chem Lett; 2021 Feb; 12(7):1793-1802. PubMed ID: 33577324
[TBL] [Abstract][Full Text] [Related]
15. Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern.
Kim TY; Jeon S; Ko M; Du YE; Son SR; Jang DS; Kim S; Lee CJ
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0120122. PubMed ID: 36374087
[TBL] [Abstract][Full Text] [Related]
16. Marine sulfated glycans inhibit the interaction of heparin with S-protein of SARS-CoV-2 Omicron XBB variant.
He P; Song Y; Jin W; Li Y; Xia K; Kim SB; Dwivedi R; Farrag M; Bates J; Pomin VH; Wang C; Linhardt RJ; Dordick JS; Zhang F
Glycoconj J; 2024 Apr; 41(2):163-174. PubMed ID: 38642280
[TBL] [Abstract][Full Text] [Related]
17. The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.
Tietjen I; Cassel J; Register ET; Zhou XY; Messick TE; Keeney F; Lu LD; Beattie KD; Rali T; Tebas P; Ertl HCJ; Salvino JM; Davis RA; Montaner LJ
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0077221. PubMed ID: 34543092
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
19. Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.
Tree JA; Turnbull JE; Buttigieg KR; Elmore MJ; Coombes N; Hogwood J; Mycroft-West CJ; Lima MA; Skidmore MA; Karlsson R; Chen YH; Yang Z; Spalluto CM; Staples KJ; Yates EA; Gray E; Singh D; Wilkinson T; Page CP; Carroll MW
Br J Pharmacol; 2021 Feb; 178(3):626-635. PubMed ID: 33125711
[TBL] [Abstract][Full Text] [Related]
20. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
